her2bi-armed activated t cells
Cell therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01147016)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Castration · Phase 2
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1
- Hamartoma · Phase 1
- Liver Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Stomach Neoplasms · Phase 1
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- her2bi-armed activated t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03406858 | Phase 2 | Jun 7, 2018 | National Cancer Institute (NCI), Wayne State University |
| NCT02662348 | Phase 1 | Feb 1, 2016 | Abingen Ltd, Nanjing Medical University |
| NCT02470559 | Phase 1 | Jun 1, 2015 | National Cancer Institute (NCI), Wayne State University |
| NCT01022138 | Phase 2 | Feb 1, 2011 | National Cancer Institute (NCI), Wayne State University |
| NCT01147016 | Phase 2 | Jul 1, 2010 | National Cancer Institute (NCI), Wayne State University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2010 |
| Wayne State University | Academic/Hospital | 4 | 4 | 2 | 2010 |
| Abingen Ltd | For profit | 1 | 0 | 1 | 2016 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1